Pangea Laboratory Partners with Gene Solutions to Advance AI-Driven Cancer Detection Technologies
- Pangea Laboratory partners with Gene Solutions to enhance cancer detection using AI-driven liquid biopsy assays.
- The collaboration will validate assays for early cancer detection and precision oncology in CLIA/CAP-certified settings.
- CEO John Moore highlights the potential for improved patient care through advanced diagnostic solutions in oncology.
Pangea Laboratory and Gene Solutions Forge Alliance to Enhance Cancer Detection
Pangea Laboratory, a prominent player in molecular diagnostics and Next-Generation Sequencing (NGS), enters into a strategic collaboration with Gene Solutions to advance cancer detection through AI-driven liquid biopsy assays. This partnership aims to validate innovative diagnostic tools that will ultimately be offered as laboratory developed tests (LDTs) in CLIA/CAP-certified settings across the United States. By leveraging Pangea's extensive validation platform and regulatory expertise, the collaboration seeks to enhance the accuracy and accessibility of cancer diagnostics for patients in the U.S.
The focus of this collaboration centers on the validation of two flagship assays: SPOT-MAS, which is designed for Multi-Cancer Early Detection (MCED) and can identify early cancer signals from a single 10 mL blood draw across ten major cancer types and 75 subtypes, and K-4CARE, a precision oncology assay that combines genomic and transcriptomic profiling with Molecular Residual Disease (MRD) detection. This initiative is critical as it builds upon Pangea's existing Bladder CARE™ test, thereby expanding its diagnostic capabilities in oncology and addressing the urgent need for early cancer detection.
John Moore, CEO of Pangea, underscores the collaboration's potential to improve patient care through advanced diagnostic solutions, while Gene Solutions' Chief Data Science Officer, Dr. Hoa Giang, emphasizes the role of AI innovations in delivering affordable cancer detection tools. With Gene Solutions providing funding, standard operating procedures, and technical support from its facilities in Singapore and Vietnam, the partnership stands to significantly impact cancer diagnosis and treatment selection, marking a milestone in the quest for more effective cancer management strategies.
In a related development within the diagnostics landscape, Zepto Life Technology has launched the FungiFlex® Mold Panel, a plasma-based molecular diagnostic test that enables rapid detection of invasive fungal infections (IFIs). This innovative test identifies cell-free DNA from 14 clinically significant mold species within 24 hours, significantly improving upon traditional diagnostic methods that are often slow and invasive.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

